To evaluate panitumumab plus modified fluorouracil , leucovorin , and oxaliplatin ( mFOLFOX@ ) or bevacizumab plus mFOLFOX@ in patients with previously untreated wild-type ( WT ) KRAS exon @ ( codons @ and @ ) metastatic colorectal cancer ( mCRC ) .